[go: up one dir, main page]

PE20061397A1 - Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion - Google Patents

Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion

Info

Publication number
PE20061397A1
PE20061397A1 PE2006000378A PE2006000378A PE20061397A1 PE 20061397 A1 PE20061397 A1 PE 20061397A1 PE 2006000378 A PE2006000378 A PE 2006000378A PE 2006000378 A PE2006000378 A PE 2006000378A PE 20061397 A1 PE20061397 A1 PE 20061397A1
Authority
PE
Peru
Prior art keywords
nitro
preparation
sulfoximino
salts
products
Prior art date
Application number
PE2006000378A
Other languages
English (en)
Inventor
Ulrich Lucking
Georg Kettschau
Wolfgang Schwede
Karl-Heinz Thierauch
Manfred Husemann
Martina Schafer
Hans Briem
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20061397A1 publication Critical patent/PE20061397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA SULFOXIMINA MACROCICLICA DE FORMULA I, DONDE A ES FENILENO O HETEROARILENO C5-C6; X ES UNA CADENA ALQUILENA C2-C6 OPCIONALMENTE SUSTITUIDA CON HALOGENO, CIANO, AMINO, ENTRE OTROS; Y ES NR4, O, S; R1 Y R2 SON H, OH, HALOGENO, NITRO, ENTRE OTROS; R3 ES H, NITRO, CIANO, AMINO, BENZODIOXOLILO, ENTRE OTROS; R4 ES H O ALQUILO C1-C8. ES UN COMPUESTO PREFERIDO (RS)-4-IMINO-15-IODO-35-NITRO-4-TIA-2,9-DIAZA-1(2,4)-PIRIMIDIN-3(1,3)-BENCENACICLONONAFAN-4-OXIDO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES QUE ESTAN ACOMPANADAS POR CRECIMIENTO VASCULAR DESREGULADO YA QUE INTERFIEREN CON LA ANGIOPOYETINA E INFLUYEN EN LA SENALIZACION DE Tie2
PE2006000378A 2005-04-08 2006-04-07 Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion PE20061397A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05090098A EP1710246A1 (en) 2005-04-08 2005-04-08 Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
US67064005P 2005-04-13 2005-04-13

Publications (1)

Publication Number Publication Date
PE20061397A1 true PE20061397A1 (es) 2007-01-26

Family

ID=34938429

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000378A PE20061397A1 (es) 2005-04-08 2006-04-07 Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion

Country Status (11)

Country Link
US (1) US20060252782A1 (es)
EP (2) EP1710246A1 (es)
JP (1) JP2008546636A (es)
AR (1) AR056863A1 (es)
CA (1) CA2604353A1 (es)
DO (1) DOP2006000084A (es)
GT (1) GT200600138A (es)
PE (1) PE20061397A1 (es)
TW (1) TW200716654A (es)
UY (1) UY29469A1 (es)
WO (1) WO2006108695A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567892A (en) 2005-11-08 2010-12-24 Vertex Pharma Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
JP5165586B2 (ja) * 2005-12-28 2013-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
WO2009089851A1 (en) * 2008-01-17 2009-07-23 Bayer Schering Pharma Aktiengesellschaft Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
JP2011518836A (ja) * 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2011051864A1 (en) 2009-11-02 2011-05-05 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
HK1206338A1 (en) 2012-05-22 2016-01-08 北卡罗来纳大学教堂山分校 Pyrimidine compounds for the treatment of cancer
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) * 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
PL3068392T3 (pl) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których pośredniczy cftr
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
CN107110831B (zh) 2014-11-18 2020-02-21 弗特克斯药品有限公司 进行高通量试验高效液相色谱的方法
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
CA2999931A1 (en) 2015-09-29 2017-04-06 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
CA3001085A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187189A (en) * 1991-01-22 1993-02-16 American Home Products Corporation S-aminoalkyl-s-arylsulfoximines as antiarrhythmic agents
EP1483260A1 (de) * 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP1879900A2 (en) 2008-01-23
US20060252782A1 (en) 2006-11-09
JP2008546636A (ja) 2008-12-25
CA2604353A1 (en) 2006-10-19
GT200600138A (es) 2007-03-19
EP1710246A1 (en) 2006-10-11
WO2006108695A3 (en) 2007-02-22
AR056863A1 (es) 2007-10-31
UY29469A1 (es) 2006-10-31
WO2006108695A2 (en) 2006-10-19
DOP2006000084A (es) 2006-11-15
TW200716654A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
PE20061397A1 (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
CR10383A (es) Derivados triazolopirazina.
NI200600094A (es) Compuesto heterociclicos fusionados
ATE517882T1 (de) Chinolinderivate
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GT200300292A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
UY28333A1 (es) Inhibidores de caspasa y sus usos.
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
PA8589801A1 (es) Aminoalcoxiindoles
TW200626158A (en) Naphthaline derivatives
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
TW200637817A (en) 5-aminoindole derivatives
GT200500383A (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos
GT200300066A (es) Derivados de ciclopenteno

Legal Events

Date Code Title Description
FC Refusal